Alpha Cognition Inc. (NASDAQ: ACOG) will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, at the Marriott Marquis Hotel in New York City. This participation highlights the conference's mission to showcase innovative companies positioned for long-term growth, particularly in the healthcare sector where Alpha Cognition focuses on developing treatments for neurodegenerative diseases.
The company's work addresses critical gaps in medical treatment, specifically targeting Alzheimer's Disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), conditions that currently lack approved treatment options. This focus makes Alpha Cognition's presentation particularly significant for investors seeking opportunities in the biopharmaceutical sector where unmet medical needs represent substantial market potential.
Michael McFadden, CEO of Alpha Cognition, emphasized the importance of this platform for sharing the company's commercial and pipeline progress. The conference provides a strategic opportunity to connect with new investors and strengthen relationships within the capital markets community, essential for advancing clinical development programs in the capital-intensive biopharmaceutical industry.
John D. Lowry, Founder and CEO of Spartan Capital Securities, noted that his firm has built its reputation on helping growth companies access appropriate investors and resources. The conference serves as an extension of this mission, bringing together high-quality issuers and serious capital providers in a focused environment. Organized in partnership with B2i Digital, the event will feature more than 60 carefully selected companies across multiple high-growth sectors, with over 500 institutional and high-net-worth investors expected to attend.
David Shapiro, CEO of B2i Digital, explained that Alpha Cognition was specifically invited to share their perspective with attending investors as part of their broader commitment to connecting investors with diverse growth companies. The event format includes main-stage presentations, expert panels, curated one-on-one meetings, and extensive networking sessions designed to create meaningful dialogue between growth companies and the investment community. For conference registration details, visit https://spartancapital.com.
The significance of Alpha Cognition's participation extends beyond immediate fundraising opportunities. As a commercial-stage biopharmaceutical company, their presence at such conferences helps validate their scientific approach and business strategy within the investment community. This visibility can accelerate partnerships, facilitate future financing rounds, and ultimately speed the development of treatments for conditions affecting millions of patients worldwide. The company's focus on neurodegenerative diseases addresses one of healthcare's most challenging areas, where successful treatments could transform patient care and create substantial value for stakeholders.
